Outcome of Second Line Chemotherapy (Gemcitabine, Dexamethasone, and Cisplatin) in Relapsed and Refractory Non Hodgkin Lymphoma

Third line Treatment in Relapsed/Refractory Hodgkin's Lymphoma and Aggressive non-Hodgkin Lymphoma after 2nd line ESHAP or GEMOX

Bendamustine in Refractory / Relapsed Non Hodgkin Lymphoma

Relapse in Patients with Non-Hodgkin’s Lymphpma

Treatment of relapsed classical Hodgkin lymphoma in the Brentuximab vedoitn era.

Long Term Outcomes of Relapsed/Refractory Non-Hodgkin Lymphoma:
A Single Center Experience

ESHAP versus GEMOX in Management of Relapsed or Refractory Lymphoma: A Prospective Randomized Study

Diffuse large B -Cell Lymphoma ESMO Summary of recommendations

Clinicopathological features of relapsed diffuse large B-cell lymphoma: South Egypt Cancer Institute experience

Treatment Outcome and Prognostic Factors in Children and Adolescents with Relapsed and Refractory Classic Hodgkin Lymphoma...